Bsense Bio Therapeutics is a pioneering biotechnology company focused on developing innovative small molecules to address sensory hyperexcitability disorders, such as chronic pain and tinnitus. By targeting two specific cation channels, TRPV1 and Kv7.2/3, co-localized on sensory nociceptive neurons, Bsense Bio employs a unique dual-action strategy that enhances therapeutic potency while ensuring a safe and non-addictive profile. This groundbreaking approach aims to effectively modulate neuronal excitability, presenting a novel therapeutic potential in pain management.

Led by a seasoned team of experts, including CEO Haim Belinson, who brings over 15 years of neurobiology research experience, Bsense Bio is dedicated to advancing its drug development pipeline. Their research is backed by preclinical proof-of-concept and is designed to meet the unmet needs in pain therapeutics. With a commitment to innovation, the company seeks to revolutionize treatment methodologies in the biotech landscape, paving the way for safer and more effective solutions in patient care.